SigmaDrugs Research Ltd.
Budapest-based biotech start-up (founded 2015) focusing on preclinical development of small-molecule therapeutics that target the Sigma-1 receptor for treatment of organ fibrosis (kidney, lung, eye) and on development of organ preservation solutions to improve transplantation outcomes. The group conducts in vitro and in vivo translational research, files and prosecutes patents, and collaborates with academic partners and international conferences.
Industries
Nr. of Employees
small (1-50)
SigmaDrugs Research Ltd.
Attila út 117. V. em. 4., Budapest, 1012, Hungary
Patents
Products
Organ preservation solution (preclinical)
A formulated preservation solution intended for cold storage of donor organs to protect grafts and improve transplantation outcomes; associated with patent filings.
Sigma-1 receptor agonist therapeutic program (preclinical)
Preclinical therapeutic program focused on sigma-1 receptor agonists for treating organ fibrosis (kidney, lung, ocular) including candidates tested in cell and rodent models.
Organ preservation solution (preclinical)
A formulated preservation solution intended for cold storage of donor organs to protect grafts and improve transplantation outcomes; associated with patent filings.
Sigma-1 receptor agonist therapeutic program (preclinical)
Preclinical therapeutic program focused on sigma-1 receptor agonists for treating organ fibrosis (kidney, lung, ocular) including candidates tested in cell and rodent models.
Services
Collaborative execution of in vitro and in vivo studies to evaluate therapeutic candidates and preservation solutions in fibrosis and transplantation research.
Collaborative execution of in vitro and in vivo studies to evaluate therapeutic candidates and preservation solutions in fibrosis and transplantation research.
Expertise Areas
- Antifibrotic drug discovery
- Organ preservation and transplantation research
- Preclinical translational research (rodent models)
- Ophthalmic drug development and trabecular meshwork biology
Key Technologies
- Sigma-1 receptor pharmacology
- 3D organoid models
- In vitro cell culture and molecular assays
- Rodent transplantation and ischemia/reperfusion models
News & Updates
Peer-reviewed article describing sigma-1 receptor as a target in diabetic kidney disease (International Journal of Molecular Sciences, 2024).
Study reporting sigma-1 receptor activation improves cold preservation outcomes in rodent kidney transplants (International Journal of Molecular Sciences, 2023).
Article reporting sigma-1 receptor agonist effects on trabecular meshwork cell fibrosis (International Journal of Molecular Sciences, 2023).
Patent applications and granted patents for organ preservation compositions and therapeutic uses of sigma-1 receptor agonists in multiple jurisdictions.
Poster presentation on sigma-1 receptor agonist effects on trabecular meshwork fibrosis at ARVO 2023.
Peer-reviewed article describing sigma-1 receptor as a target in diabetic kidney disease (International Journal of Molecular Sciences, 2024).
Study reporting sigma-1 receptor activation improves cold preservation outcomes in rodent kidney transplants (International Journal of Molecular Sciences, 2023).
Article reporting sigma-1 receptor agonist effects on trabecular meshwork cell fibrosis (International Journal of Molecular Sciences, 2023).
Patent applications and granted patents for organ preservation compositions and therapeutic uses of sigma-1 receptor agonists in multiple jurisdictions.
Poster presentation on sigma-1 receptor agonist effects on trabecular meshwork fibrosis at ARVO 2023.